<DOC>
	<DOCNO>NCT00780715</DOCNO>
	<brief_summary>This proposal fund pilot study assess feasibility refine methodology intend large Scotland wide study Response Oral Agents Diabetes ( ROAD ) . The study collect cohorts patient carefully control standardise dose titration monitoring assessment drug response side effect 6 month period . The primary aim use cohort investigate phenotypic genotypic ( pharmacogenetic ) determinant response . Drug na√Øve patient treat Metformin . Patients fail Metformin intolerant Metformin randomise gliclazide , pioglitazone sitagliptin . With ability capture patient data beyond 6 month via data linkage monitor time treatment failure therefore compare 3 oral agent best therapy use Metformin cost efficient `` real world '' RCT .</brief_summary>
	<brief_title>Response To Oral Agents Diabetes ( ROAD ) - Pilot Study</brief_title>
	<detailed_description>The Response Oral Agents Diabetes ( ROAD ) study aim address limitation observational data create prospective study incident user oral agent . For first six month research team ensure protocol driven dose titration , standardise monitoring adherence , response side effect standardise deviation therapy . Thereafter patient receive 6 monthly monitoring protocol lead dose titration GP . Biochemistry , prescribe data , morbidity mortality data capture 10 year drug initiation . The ROAD study provide highly power prospective cohort investigate phenotypic genotypic determinant response right . However , cohort use synergistically ongoing observational pharmacogenetics study , allow crucial replication 'positive ' signal . Furthermore , randomisation drug initiation , long term community follow allow comparison time treatment failure patient treat gliclazide , pioglitazone sitagliptin much cost effective 'real-world ' set traditional prospective randomise trial This pilot study assess feasibility large complex intervention , particularly optimise patient recruitment process , questionnaire , dose titration monitoring , randomisation different second line agent . With knowledge pilot , application make large region Scotland wide study collect 2000 patient incident oral diabetes treatment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>Cohort 1 metformin treatment Type 2 diabetes diagnose 6 week prior visit 1 GP considers adequate diet lifestyle advice give Age &gt; 35 &lt; 80 Age diabetes diagnosis &gt; 35 White European HbA1c &gt; 7 % &amp; &lt; =9 % eGFR &gt; =50 ml/min ALT &lt; = 2.5*ULN Contactable telephone Cohort 2 2nd line treatment Type 2 diabetes Treated metformin 3 month ; metformin intolerant Age &gt; 35 &lt; 80 Age diabetes diagnosis &gt; 35 White European HbA1c &gt; 7 % &amp; &lt; =9 % eGFR &gt; =50 ml/min ALT &lt; = 2.5*ULN No previous history heart failure ; No patient document evidence leave ventricular systolic dysfunction OR symptoms sign consistent clinical diagnosis heart failure No treatment Gemfibrozil Rifampicin ( CYP2C8 inhibitor inducer respectively ) ; Miconazole phenylbutazone ( increased hypoglycemic effect gliclazide ) . No diagnosis osteoporosis Contactable telephone Cohort 1 Type 1 diabetes HbA1c &gt; 9 % &lt; =7 % eGFR &lt; 50 ml/min ALT &gt; 2.5*ULN Alcohol consumption excess 50 unit per week Pregnancy , lactation female planning conceive within study period Any significant medical reason exclusion determine investigator Cohort 2 Type 1 diabetes HbA1c &gt; 9 % &lt; =7 % eGFR &lt; 50 ml/min ALT &gt; 2.5*ULN Previous history heart failure OR document evidence leave ventricular systolic dysfunction OR symptoms sign consistent clinical diagnosis heart failure Ongoing treatment Gemfibrozil Rifampicin ( CYP2C8 inhibitor inducer respectively ) ; Miconazole phenylbutazone ( increased hypoglycemic effect gliclazide ) . Previous diagnosis osteoporosis Pregnancy , lactation female planning conceive within study period Any significant medical reason exclusion determine investigator</criteria>
	<gender>All</gender>
	<minimum_age>36 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Diabetes therapy</keyword>
	<keyword>Pharmacogenetics</keyword>
</DOC>